Compare WS & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | PRCT |
|---|---|---|
| Founded | 1955 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2023 | 2021 |
| Metric | WS | PRCT |
|---|---|---|
| Price | $43.56 | $23.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $47.00 | ★ $48.88 |
| AVG Volume (30 Days) | 238.3K | ★ 1.1M |
| Earning Date | 03-20-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ 21.88 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $3,093,300,000.00 | $224,498,000.00 |
| Revenue This Year | $21.33 | $39.90 |
| Revenue Next Year | $3.41 | $24.91 |
| P/E Ratio | $39.29 | ★ N/A |
| Revenue Growth | N/A | ★ 64.84 |
| 52 Week Low | $21.30 | $26.23 |
| 52 Week High | $49.17 | $65.90 |
| Indicator | WS | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 27.98 |
| Support Level | $29.63 | N/A |
| Resistance Level | $44.00 | $36.93 |
| Average True Range (ATR) | 1.78 | 1.66 |
| MACD | -0.65 | -0.20 |
| Stochastic Oscillator | 18.22 | 38.80 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.